A study, published in The New England Journal of Medicine, compared drug-eluting bioresorbable vascular scaffolds with drug-eluting metallic stents in percutaneous coronary interventions. Abbott ...

Please provide your email address to receive an email when new articles are posted on . An aragonite-based scaffold for chondral defects had better outcomes vs. microfracture. Women had the same or ...

Please provide your email address to receive an email when new articles are posted on . Researchers randomly assigned 261 patients with chronic limb-threatening ischemia (CLTI) on a 2:1 basis to ...

A drug-eluting resorbable scaffold continues to keep many patients with below-the-knee (BTK) chronic limb-threatening ischemia (CLTI) free from repeat procedures, even after most of the device’s ...

LAS VEGAS, NV—At 2 years, a drug-eluting resorbable scaffold continues to show sustained patency and safety compared with conventional angioplasty alone in patients with below-the-knee (BTK) chronic ...

San Francisco — An everolimus-eluting stent with a resorbable scaffold showed superior efficacy in a randomized multicenter trial when compared with angioplasty for the treatment of patients with ...

The trial's primary efficacy endpoint -- freedom from amputation above the ankle of the target limb, occlusion of the target vessel, clinically driven revascularization of the target lesion, and ...

AMSTERDAM, NL — Consistent with prior trials, the risk of scaffold thrombosis was significantly higher in patients receiving the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) than an ...